 The goal of this study is to evaluate safety and efficacy of bone marrow BM as site for pancreatic islet transplantationin humans. Our hypothesis is that BM represents a better site than liver currently the location of choice for this procedure thanks to its potential capacity to favor islet engraftment. To address our hypothesis we propose herein a randomized phase II trial to compare BM and liver as sites for islet transplantation in T1D patients. 